HUP0203957A2 - Az érképződést és az érrendszeri permeabilitást módosító és gátló hatóanyagok - Google Patents
Az érképződést és az érrendszeri permeabilitást módosító és gátló hatóanyagokInfo
- Publication number
- HUP0203957A2 HUP0203957A2 HU0203957A HUP0203957A HUP0203957A2 HU P0203957 A2 HUP0203957 A2 HU P0203957A2 HU 0203957 A HU0203957 A HU 0203957A HU P0203957 A HUP0203957 A HU P0203957A HU P0203957 A2 HUP0203957 A2 HU P0203957A2
- Authority
- HU
- Hungary
- Prior art keywords
- protein
- src
- modified
- yes
- inhibitors
- Prior art date
Links
- 230000008728 vascular permeability Effects 0.000 title abstract 5
- 230000033115 angiogenesis Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- ZVPDNRVYHLRXLX-UHFFFAOYSA-N 1-ter-butyl-3-p-tolyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine Chemical compound C1=CC(C)=CC=C1C1=NN(C(C)(C)C)C2=NC=NC(N)=C12 ZVPDNRVYHLRXLX-UHFFFAOYSA-N 0.000 abstract 2
- -1 PD 173955 Chemical compound 0.000 abstract 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013000 chemical inhibitor Substances 0.000 abstract 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 abstract 1
- 108091006086 inhibitor proteins Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940121649 protein inhibitor Drugs 0.000 abstract 1
- 239000012268 protein inhibitor Substances 0.000 abstract 1
- WYZWZEOGROVVHK-GTMNPGAYSA-N radicicol Chemical compound C/1=C/C=C/C(=O)CC2=C(Cl)C(O)=CC(O)=C2C(=O)O[C@H](C)C[C@H]2O[C@@H]2\1 WYZWZEOGROVVHK-GTMNPGAYSA-N 0.000 abstract 1
- 102000009076 src-Family Kinases Human genes 0.000 abstract 1
- 108010087686 src-Family Kinases Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Environmental Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány módszereket közöl vaszkuláris permeabilitás (VP)módosítására szövetekben, Src vagy módosított Src protein, Yes proteinvagy módosított Yes protein, Src családhoz tartozó tirozinkináz-gátlóproteinek, valamint Src vagy módosított Src protein, Yes protein vagymódosított Yes protein, valamint Src családhoz tartozó tirozin-kináz-protein inhibitorok, valamint ezek keverékeinek a expressziójára képesnukleinsavak alkalmazásával. A találmány továbbá módszereket ismertetVP gátlására inaktív; Src vagy Yes protein vagy ezek keverékeinek azalkalmazásával, valamint CSK protein vagy módosított CSK protein, vagyezek kódolására megfelelő nukleinsavak alkalmazásával; vagy kémiaijellegű Src családhoz tartozó tirozinkináz-inhibitorokfelhasználásával, vagy VP potencírozására aktív Src vagy Yes proteinvagy ezek keverékének az alkalmazásával; vagy az előbbi hatóanyagokatkódoló nukleinsavak alkalmazásával. Kémiai jellegű inhibitorokkéntalkalmazhatók például: a PP1, PP2, PD 173955, AGL 1872, PD 16253 l,Radicicol R2146 és Geldanamycin. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/470,881 US6685938B1 (en) | 1998-05-29 | 1999-12-22 | Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases |
| US53824800A | 2000-03-29 | 2000-03-29 | |
| PCT/US2000/035396 WO2001045751A1 (en) | 1999-12-22 | 2000-12-22 | Angiogenesis and vascular permeability modulators and inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0203957A2 true HUP0203957A2 (hu) | 2003-03-28 |
| HUP0203957A3 HUP0203957A3 (en) | 2005-07-28 |
| HU229628B1 HU229628B1 (en) | 2014-03-28 |
Family
ID=27043259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203957A HU229628B1 (en) | 1999-12-22 | 2000-12-22 | Angiogenesis and vascular permeability modulators and inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1250155B1 (hu) |
| JP (1) | JP2003518077A (hu) |
| KR (1) | KR100813818B1 (hu) |
| CN (1) | CN1434727A (hu) |
| AT (2) | ATE392215T1 (hu) |
| AU (1) | AU781444B2 (hu) |
| BR (1) | BR0016547A (hu) |
| CA (1) | CA2395136A1 (hu) |
| CZ (1) | CZ304320B6 (hu) |
| DE (1) | DE60038631T2 (hu) |
| DK (2) | DK1905457T3 (hu) |
| ES (2) | ES2383763T3 (hu) |
| HU (1) | HU229628B1 (hu) |
| NO (1) | NO20023036L (hu) |
| PL (1) | PL356815A1 (hu) |
| PT (2) | PT1250155E (hu) |
| RU (1) | RU2271216C2 (hu) |
| SK (1) | SK287575B6 (hu) |
| WO (1) | WO2001045751A1 (hu) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030130209A1 (en) | 1999-12-22 | 2003-07-10 | Cheresh David A. | Method of treatment of myocardial infarction |
| ATE328888T1 (de) | 2000-08-25 | 2006-06-15 | Sloan Kettering Inst Cancer | Radicicol und monocillin und ihre analogen und ihre anwendungen |
| JP2006507021A (ja) * | 2002-03-18 | 2006-03-02 | メドトロニック・エイヴイイー・インコーポレーテッド | 再狭窄の危険のある解剖学的部位へ抗増殖性組成物を送付するための医療用具 |
| CN1681525A (zh) * | 2002-07-12 | 2005-10-12 | 曹义海 | 一种抑制血管渗漏和组织水肿的方法 |
| EP1413887A1 (en) * | 2002-10-22 | 2004-04-28 | Aventis Pharma S.A. | Inhibitors of Src kinase for use in Alzheimer's disease |
| AU2003295268A1 (en) * | 2002-12-19 | 2004-07-14 | To-Bbb Holding B.V. | Nucleic acids involved in blood-brain barrier control |
| GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
| ATE481134T1 (de) * | 2004-01-21 | 2010-10-15 | Univ Emory | Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen |
| US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
| EP1965762A1 (en) * | 2005-12-23 | 2008-09-10 | Alcon, Inc. | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| BRPI0711901A2 (pt) * | 2006-05-22 | 2012-03-06 | The Regents Of The University Of California | Composições e métodos para a liberação de oxigênio |
| DK1862802T3 (da) * | 2006-06-01 | 2009-04-14 | Cellzome Ag | Fremgangsmåde til identifikation af med ZAP-70 vekselvirkende molekyler og til rensning af ZAP-70 |
| DE102007037008B4 (de) * | 2007-08-06 | 2015-09-10 | Siemens Aktiengesellschaft | Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors |
| WO2011053048A2 (ko) * | 2009-10-29 | 2011-05-05 | 연세대학교 산학협력단 | 신규 혈관누출 차단제 |
| US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
| US10293023B2 (en) | 2013-03-15 | 2019-05-21 | Children's Medical Center Corporation | Method of altering vascular permeability and uses thereof |
| CN105288654B (zh) * | 2015-01-23 | 2018-11-30 | 中国人民解放军第二军医大学 | 蛋白酪氨酸激酶fyn癌基因在防治肠道病毒71型感染中的应用 |
| CN105311645B (zh) * | 2015-01-23 | 2018-11-30 | 中国人民解放军第二军医大学 | 胚胎fyn相关底物efs在防治肠道病毒71型感染中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356167A (en) | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
| US5092885A (en) | 1987-02-12 | 1992-03-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides with laminin activity |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
| ATE120860T1 (de) * | 1990-01-26 | 1995-04-15 | Washington Res Found | Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten. |
| EP0470569B1 (en) | 1990-08-08 | 1995-11-22 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis inhibiting substance |
| US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| US5922697A (en) * | 1996-10-02 | 1999-07-13 | Warner-Lambert Company | Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins |
| US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
| ATE292623T1 (de) * | 1997-05-07 | 2005-04-15 | Sugen Inc | 2-indolinonderivate als modulatoren der proteinkinase-ativität |
| US6723694B1 (en) * | 1997-05-21 | 2004-04-20 | The Children's Medical Center Corp. | Short peptides which selectively modulate intracellular signalling |
| US6420338B1 (en) * | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| JP2001518502A (ja) * | 1997-10-06 | 2001-10-16 | ビーエーエスエフ アクチェンゲゼルシャフト | チロシンキナーゼ活性を阻害するためのインデノ［１，２−ｃ］ピラゾール誘導体 |
| DK1082415T3 (da) * | 1998-05-29 | 2011-06-14 | Scripps Research Inst | Anvendelige fremgangsmåder til modulation af angioge-nese ved anvendelse af tyrosin kinase SRC |
| CZ20011564A3 (cs) * | 1998-11-06 | 2002-04-17 | Basf Aktiengesellschaft | Léčivo pro inhibici vaskulární hyperpermeability |
-
2000
- 2000-12-22 EP EP00990365A patent/EP1250155B1/en not_active Expired - Lifetime
- 2000-12-22 SK SK849-2002A patent/SK287575B6/sk not_active IP Right Cessation
- 2000-12-22 HU HU0203957A patent/HU229628B1/hu not_active IP Right Cessation
- 2000-12-22 JP JP2001546690A patent/JP2003518077A/ja active Pending
- 2000-12-22 AT AT00990365T patent/ATE392215T1/de active
- 2000-12-22 DE DE60038631T patent/DE60038631T2/de not_active Expired - Lifetime
- 2000-12-22 DK DK07020078.7T patent/DK1905457T3/da active
- 2000-12-22 ES ES07020078T patent/ES2383763T3/es not_active Expired - Lifetime
- 2000-12-22 CA CA002395136A patent/CA2395136A1/en not_active Abandoned
- 2000-12-22 PL PL00356815A patent/PL356815A1/xx not_active Application Discontinuation
- 2000-12-22 AT AT07020078T patent/ATE553782T1/de active
- 2000-12-22 ES ES00990365T patent/ES2303514T3/es not_active Expired - Lifetime
- 2000-12-22 BR BR0016547-6A patent/BR0016547A/pt not_active Application Discontinuation
- 2000-12-22 DK DK00990365T patent/DK1250155T3/da active
- 2000-12-22 KR KR1020027008102A patent/KR100813818B1/ko not_active IP Right Cessation
- 2000-12-22 PT PT00990365T patent/PT1250155E/pt unknown
- 2000-12-22 PT PT07020078T patent/PT1905457E/pt unknown
- 2000-12-22 EP EP07020078A patent/EP1905457B1/en not_active Expired - Lifetime
- 2000-12-22 WO PCT/US2000/035396 patent/WO2001045751A1/en active Application Filing
- 2000-12-22 RU RU2002119399/15A patent/RU2271216C2/ru not_active IP Right Cessation
- 2000-12-22 CZ CZ2002-2156A patent/CZ304320B6/cs not_active IP Right Cessation
- 2000-12-22 AU AU27400/01A patent/AU781444B2/en not_active Ceased
- 2000-12-22 CN CN00819151A patent/CN1434727A/zh active Pending
-
2002
- 2002-06-21 NO NO20023036A patent/NO20023036L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2383763T3 (es) | 2012-06-26 |
| HUP0203957A3 (en) | 2005-07-28 |
| PT1250155E (pt) | 2008-06-06 |
| CZ304320B6 (cs) | 2014-03-05 |
| ES2303514T3 (es) | 2008-08-16 |
| RU2271216C2 (ru) | 2006-03-10 |
| KR100813818B1 (ko) | 2008-03-17 |
| DE60038631T2 (de) | 2009-06-10 |
| EP1250155A1 (en) | 2002-10-23 |
| DK1905457T3 (da) | 2012-05-29 |
| SK8492002A3 (en) | 2002-11-06 |
| CN1434727A (zh) | 2003-08-06 |
| BR0016547A (pt) | 2002-10-29 |
| NO20023036L (no) | 2002-07-22 |
| RU2002119399A (ru) | 2004-02-27 |
| EP1250155A4 (en) | 2003-08-20 |
| NO20023036D0 (no) | 2002-06-21 |
| ATE553782T1 (de) | 2012-05-15 |
| JP2003518077A (ja) | 2003-06-03 |
| DE60038631D1 (de) | 2008-05-29 |
| AU2740001A (en) | 2001-07-03 |
| AU781444B2 (en) | 2005-05-26 |
| SK287575B6 (sk) | 2011-03-04 |
| PT1905457E (pt) | 2012-05-25 |
| KR20020063259A (ko) | 2002-08-01 |
| WO2001045751A1 (en) | 2001-06-28 |
| CA2395136A1 (en) | 2001-06-28 |
| EP1905457A1 (en) | 2008-04-02 |
| ATE392215T1 (de) | 2008-05-15 |
| EP1250155B1 (en) | 2008-04-16 |
| DK1250155T3 (da) | 2008-08-25 |
| HU229628B1 (en) | 2014-03-28 |
| EP1905457B1 (en) | 2012-04-18 |
| PL356815A1 (en) | 2004-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0203957A2 (hu) | Az érképződést és az érrendszeri permeabilitást módosító és gátló hatóanyagok | |
| HUP0402303A2 (hu) | Módosított VII-es faktor polipeptidek folyékony készítménye | |
| MY162068A (en) | Formulation of human antibodies for treating tnf-(alpha) associated disorders | |
| HUP0301842A2 (hu) | Laktám vegyület, a vegyületet tartalmazó gyógyszerkészítmény és alkalmazása gyógyszerkészítmény elżállítására | |
| HUP0300340A3 (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases, pharmaceutical compositions containing them and their use | |
| HUP0301356A2 (hu) | Új, DPPIV-gyel rokon szerin proteáz gének | |
| IS6491A (is) | Pteridínefnasambönd til meðhöndlunar á sóríasis | |
| NO20050932L (no) | 1-pyridin-4-yl-ureaderivater | |
| NO20034230L (no) | 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister | |
| NO954320L (no) | Lyosfærer omfattende gonadotropin | |
| TW200514772A (en) | Novel tetrahydropyridine derivatives | |
| MXPA02010648A (es) | Formulaciones liquidas. | |
| DK1330455T3 (da) | Hidtil ukendte 7-azaindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling | |
| ATE297222T1 (de) | Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis | |
| DE60040089D1 (de) | Menschliches homolog aus der familie der metalloproteasen | |
| BR9910787A (pt) | Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src | |
| WO2002059327A3 (en) | Sulfatases and methods of use thereof | |
| UA84831C2 (ru) | Производные фактора коагуляции vii | |
| MXPA02009781A (es) | Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas. | |
| WO2002046458A3 (en) | Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof | |
| ATE389029T1 (de) | Protease assay zur kontrolle medikamentöser therapie | |
| WO2001068868A3 (en) | Alpha(iii) subunit of prolyl 4-hydroxylase | |
| DE60333747D1 (de) | Dna-enzym zur hemmung von plasminogenaktivator-inhibitor-1 | |
| ATE402178T1 (de) | Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten | |
| SE0202608D0 (sv) | New sequences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |